Deutsche Bank Reiterates CHF 90 Price Target for Novartis (VTX:NOVN)

Deutsche Bank set a CHF 90 price target on Novartis (VTX:NOVN) in a report released on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

NOVN has been the subject of a number of other research reports. Morgan Stanley set a CHF 83 target price on shares of Novartis and gave the company a sell rating in a research report on Thursday, May 30th. Kepler Capital Markets set a CHF 87 target price on shares of Novartis and gave the company a buy rating in a research report on Tuesday, May 21st. Jefferies Financial Group set a CHF 100 target price on shares of Novartis and gave the company a buy rating in a research report on Friday, August 30th. Credit Suisse Group set a CHF 88 target price on shares of Novartis and gave the company a neutral rating in a research report on Friday, July 19th. Finally, Goldman Sachs Group set a CHF 105 target price on shares of Novartis and gave the company a buy rating in a research report on Friday, September 13th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Novartis presently has an average rating of Hold and a consensus price target of CHF 90.85.

Novartis has a 52-week low of CHF 72.45 and a 52-week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: Fundamental Analysis

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit